Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264164 | 1.00 | MCHR1 (0.47) | MCHR1KCNQ3KCNQ2JAK1NPC1 | |
| Hydrochloric Acid SCHEMBL4256601 | 0.99 | MCHR1 (0.46) | MCHR1KCNQ3KCNQ2JAK1NPC1 | |
| Hydrochloric Acid SCHEMBL4256596 | 0.99 | MCHR1 (0.46) | MCHR1KCNQ3KCNQ2JAK1NPC1 | |
| SCHEMBL4255651 | 0.91 | KMT2A (0.50) | SMN1; SMN2NR1I2AHRKMT2A | |
| SCHEMBL4255650 | 0.91 | KMT2A (0.50) | SMN1; SMN2NR1I2AHRKMT2A | |
| Hydrochloric Acid SCHEMBL4256042 | 0.91 | KMT2A (0.49) | MCHR1SMN1; SMN2NR1I2AHRKMT2A | |
| Hydrochloric Acid SCHEMBL4256048 | 0.91 | KMT2A (0.49) | MCHR1SMN1; SMN2NR1I2AHRKMT2A | |
| SCHEMBL4256525 | 0.90 | MCHR1 (0.39) | MCHR1KDRABL1 | |
| SCHEMBL4256520 | 0.90 | MCHR1 (0.39) | MCHR1KDRABL1 | |
| Hydrochloric Acid SCHEMBL4263572 | 0.89 | ABL1 (0.39) | MCHR1KDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | MCHR1 3/4885KCNQ3 3071/4885KCNQ2 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.